Provided herein are methods for pre-activating and expanding an isolated population of NK cells. Further provided herein are methods for the treatment of cancer by administering the pre-activated and expanded NK cells.

Disclosed are compositions and methods for treating cancers characterized by the presence of solid tumors, which simultaneously target a plurality of targets on cancer cells using single CAR T construct.

Provided herein are methods for pre-activating and expanding an isolated population of NK cells. Further provided herein are methods for the treatment of cancer by administering the pre-activated and expanded NK cells.

The present invention refers to a bispecific in tandem receptor CAR, named RfuCAR, which includes a scFv that recognizes and ligates surface molecules on tumoral cells (CD33, CD123 or another tumoral target) and the IL-1 receptor type 2 (IL-1R2). According to this, the IL1-R2 was chosen as the ideal receptor to compose the RfuCAR construction, being able to capture the IL-1 with high affinity and specificity. These proprieties indicate it as a good candidate to reduce the neurotoxicity and CRS effects of CAR-T therapies. Additionally, the present invention deals with a method for modulating the tumoral microenvironment, for example, in case of acute myeloid leukemia, or other cancer type like but not restricted to acute lymbloblastic leukemia, pancreatic, lung and ovarian cancer.

A method for activating or enriching V17.sup.+CD8.sup.+ T cells, comprising contacting a M1 peptide derived from human influenza A virus (M1.sub.58-66) with a population of cells comprising T cells.

The present invention relates to a humanized anti-CD28 antibody, a multispecific antibody comprising the humanized anti-CD28 antibody, especially a bispecific antibody comprising the humanized anti-CD28 antibody and an anti-CD40 antibody, a polynucleotide encoding these antibodies, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and a pharmaceutical composition comprising same. The present invention also relates to use of the humanized anti-CD28 antibody in inducing T cell proliferation and use of the bispecific antibody in enhancing the killing effect of immune cells on a target cell.

The present disclosure relates to the preparation and use of CAR-NK cells which are modified by a nucleic acid targeting compound.

Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13R2 than IL13R1 by virtue of weaker binding to IL13R1. The chimeric antigen receptors can be used to treat IL13R2 expressing cancers.

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13R2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.